Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
  • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

• the invention relates to the identification and use of modulating compounds of the enzyme TACE for the treatment of acne.
• Acne is a skin condition that results from the occlusion of the upper extremity as well as the internal part of the pilosebaceous canal by the abnormal multiplication of keratinocytes, and the androgenic hyper-hormonal activity often appearing during puberty. , which causes a significant increase in seborrhea in the sebaceous glands.
• the obstruction of the pilosebaceous canal causes the formation of comedones or microcysts, accompanied by a proliferation of Propionibacterium acnes bacteria as well as Pytirosporum ovale in the obstructed pilosebaceous follicles.
• This condition is accompanied by an inflammatory reaction of the skin, which may be in the form of papules or pustules usually located in the superficial dermis.
• the inflammatory reaction can reach the deep dermis, forming nodules and macrocysts.
• the applicant now proposes to use inhibitors of the enzyme TACE, to prevent and / or improve acne phenomena.
• the TACE inhibitor is used alone, that is to say without other anti-acne active ingredient, or even without any other active principle.
• Acne to be treated includes all forms of acne, namely in particular vulgar acne, comedon, polymorphic, nodulocystic acne, conglobata, or secondary acne such as solar acne, drug or professional.
• TACE for "TNF-alpha converting enzyme"
• TNF-alpha converting enzyme is responsible for the production of TNF-alpha.
• This enzyme is a member of the ADAM family of metalloproteases (Becherer et al, Handb Exp Pharmacol, 2000, 140: 235-258). It quickly converts proTNF ⁇ , a 26kDa precursor protein, into protein
• TNF ⁇ mature 17kDa Inhibition of TACE (or ADAM 17) leads to inhibition of TNF ⁇ synthesis (Nelson et al., Exp Opin. Invest Drugs, 1999, 8: 383-392).
• TACE inhibitors have been shown to suppress TNF production and inflammatory response in model animals with collagen-induced arthritis (Newton et al., Ann Rheum, Dis, 2001, 60: iii25-i ⁇ 32). ). It has also been shown that P. acnes stimulates the release of TNF ⁇ by keratinocytes and macrophages (Gro et al., Br J Dermatol 2004, 150 (3): 421-428).
• TACE inhibitors have an impact on the inflammatory phenomena observed in acne, in particular via the modulation by TNF ⁇ of several genes involved in the inflammation.
• TNF ⁇ the markers of inflammatory acne lesion and reported to be induced in response to TNF ⁇ exposure are the genes involved in the following "stress response":
• SOD2 (Horrevoets et al., Blood 1999 May 15, 93 (10): 3418-31); the gene involved in the following angiogenesis: - ECGF1 (Zhu et al., Oncogene 2002 Dec 5; 21 (55): 8477-85), the genes involved in the following cell migration and remodeling: -MMP1, MMP3 (Reunanen and J Biol Chem 2002 Aug 30, 277 (35): 32360-8),
• T1-A-2 (Banno et al., J Biol Chem 2004, Jul 30, 279 (31): 32633-42, Epub 2004 May 15); the genes involved in the following immune response: DEFB4 (Seo SJ et al., J Dermatol Sci 2001 Nov; 27 (3): 183-91),
• CD14 (Enomoto et al., J. Pharmacol Exp Ther 2003 Sep 01; 306 (3): 846-54),
• CD47 (Banno et al., J Biol Chem 2004 JuI 30; 279 (31): 32633-42); FPR1 (Mandai et al., J. Immunol 2005 Nov. 01; 175 (9): 6085-91);
• TNF ⁇ inhibits the FRZB gene involved in development (Tian et al., J. Biol Chem 2005 Apr 29; 280 (17): 17435-48).
• TNF ⁇ inhibits two genes involved in metabolism:
• TACE inhibitors are in development, mainly for the treatment of arthritis.
• Many patent applications also offer TACE inhibitors, for the treatment of arthritis, cancers, or other diseases such as patent applications US200412201 1 (MASFERRER JL) and WO9942436 (AMERICAN CYANAMID). Indeed, these two applications describe treatment methods or compositions containing TACE inhibitors for the treatment of various pathologies including acne.
• TACE gene or "TACE nucleic acid” means the gene or nucleic acid that encodes the TACE enzyme. If the targeted target is preferably the human gene or its expression product, the invention may also use cells expressing a heterologous TACE, by genomic integration or transient expression of an exogenous nucleic acid encoding the enzyme.
• An object of the invention is an in vitro method for screening candidate compounds for the preventive and / or curative treatment of acne, comprising determining the ability of a compound to inhibit the expression or the TACE activity or the expression of its gene or the activity of at least one of its promoters, an inhibition of the expression or activity of TACE, or the expression of its gene or activity of at least one of its promoters indicating the utility of the compound for the preventive or curative treatment of acne.
• inhibittion is meant any diminishing effect on the expression or the activity of the enzyme, on the expression of its gene or on the activity of at least one of its promoters.
• the compounds tested can be of any type. They can be of natural origin or have been produced by chemical synthesis. It can be a library of structurally defined chemical compounds, compounds or uncharacterized substances, or a mixture of compounds. Various techniques can be implemented to test these compounds and to identify compounds of therapeutic interest, modulators of TACE expression or activity.
• the screening method comprises the following steps: a. Preparation of at least two biological samples or reaction mixtures; b. Contacting one of the samples or reaction mixtures with one or more of the test compounds; vs. Measuring the expression or the activity of the TACE enzyme, the expression of its gene or the activity of at least one of its promoters, in biological samples or reaction mixtures; d. Selection of compounds for which an inhibition of the expression or activity of the TACE enzyme, or an inhibition of the expression of its gene or an inhibition of the activity of at least one of its promoters, is measured in the sample or mixture treated in (b) in relation to the untreated sample or mixture.
• expression of an enzyme means the amount of that enzyme.
• promoter activity is meant the ability of this promoter to trigger the transcription of the coded DNA sequence downstream of this promoter (and thus indirectly the synthesis of the protein, in this case the corresponding enzyme).
• the biological samples or reaction mixtures of step a) are cells transfected with a reporter gene operably linked to all or part of the promoter of the TACE gene.
• the method is then performed by contacting a compound (step b) with these biological samples or reaction mixtures, then by determining the level of expression of said reporter gene (step c)).
• the selection of step d) is done by the observation of a difference of expression level, compared to a control carried out in the absence of the compound. This difference indicates the utility of the compound for the preventive or curative treatment of acne.
• the reporter gene may in particular encode an enzyme which, in the presence of a given substrate, leads to the formation of colored products, such as CAT (chloramphenicol acetyltransferase), GAL (beta galactosidase), or GUS (beta glucuronidase). It may also be the gene for luciferase or GFP (Green Fluorescent Protein).
• the assay of the protein encoded by the reporter gene, or of its activity, is carried out conventionally, by colorimetric, fluorometric or chemiluminescence techniques, among others.
• the biological samples or reaction mixtures of step a) are cells expressing the TACE gene coding for TACE.
• the screening method then comprises contacting a compound (step b) with the biological samples or reaction mixtures, and then determining the level of expression of said gene (step c)).
• the selection of step d) is made by the observation of a difference in expression level of the TACE gene, compared to a control carried out in the absence of the compound. This difference indicates the utility of the compound for the preventive or curative treatment of acne.
• the cell used here can be of any type. It can be a cell expressing the gene
• TACE endogenously such as a liver cell, an ovarian cell, or even better a keratinocyte or a cell of the immune system such as THP1 cells. It may also be a cell transformed with a heterologous nucleic acid, coding for TACE, preferably human, or mammalian.
• a wide variety of host cell systems can be used, such as for example Cos-7, CHO, BHK, 3T3, HEK293 cells.
• Microorganisms such as bacteria (eg E. coli or B. subtilis) can also be used. ; yeast (eg Saccharomyces, Pichia); insect cells, such as Sf9 or Sf21.
• the nucleic acid can be stably or transiently transfected by any method known to those skilled in the art, for example by calcium phosphate, DEAE-dextran, liposome, virus, electroporation, or microinjection.
• the level of expression of the TACE gene can be determined by evaluating the level of transcription of said gene, or its level of translation.
• level of transcription of a gene is meant the amount of the corresponding mRNA produced.
• translation level of a gene is meant the amount of protein produced.
• the level of translation of the gene is evaluated for example by methods of the immunoassay type, mass spectrometry analysis (MALDI-TOF and thin layer analysis), etc.
• the antibodies used may be of polyclonal or monoclonal type. Their production is based on conventional techniques.
• the immunoassay can be carried out in solid phase or in homogeneous phase; in a time or in two stages; sandwich method or competitive method, by way of non-limiting examples.
• the capture antibody is immobilized on a solid phase.
• solid phase it is possible to use microplates, in particular polystyrene microplates, or particles or solid beads, paramagnetic beads.
• ELISA assays can be used to reveal the presence of the antigen-antibody complexes formed. Characterization of antigen / antibody complexes, and more generally isolated or purified but also recombinant proteins (obtained in vitro and in vivo) can be performed by mass spectrometric analysis (proteomics).
• the biological samples or reaction mixtures of step a) are reaction mixtures comprising a TACE enzyme or, preferably, an N-terminal fragment of 610 acids of the recombinant human TACE enzyme, and a substrate of the enzyme.
• the screening method then comprises contacting a compound (step b) with these mixtures and then determining the enzymatic activity (step c)).
• the selection of step d) is done by the observation of a decrease in activity, compared to a control carried out in the absence of the compound. Such a decrease indicates the utility of the compound for the preventive or curative treatment of acne.
• the cleavage activity of the substrate by the human recombinant enzyme TACE is followed by fluorescence by excitation at 320 nm and emission at 420 nm.
• Another way to measure the activity of TACE is to measure the production of TNF ⁇ , for example by an immunoassay using HTRF (homogeneous time resolved fluorescence) technology on keratinocytes or THP1 cell cultures.
• the cells are stimulated beforehand with LPS and / or TPA and the TNF ⁇ produced by the cells is assayed with the aid of two murine antibodies, each recognizing a different epitope of human TNF ⁇ .
• Each antibody is conjugated with either europium cryptate or XL665 allophycocyanin. This combination makes it possible to measure a FRET signal when the two antibodies each bind to one end of the TNF ⁇ produced.
• Candidate TACE inhibitors can then be tested on acne models, or on patients with acne.
• the invention thus also provides a method for screening candidate compounds for the treatment and / or prevention of acne, said method comprising administering a TACE-inhibiting compound to a subject having acne-prone skin or acne-prone skin , and assessment of the condition of acne.
• the administration is preferably carried out topically.
• Topically we mean an application on the skin or the mucous membranes.
• the subject of the invention is also the use of an inhibitor of the human enzyme TACE, in particular an inhibitor obtained by the screening method described above, for the preparation of a medicinal product intended for preventive and / or curative treatment. acne.
• the drug does not contain a cyclooxygenase-2 (COX-2) inhibitor.
• the human enzyme inhibitor TACE is the only anti-acne active ingredient contained in the drug. Even more preferably, the inhibitor of the human enzyme TACE is the only active ingredient contained in the drug.
• a method of preventive and / or curative treatment of acne comprising administering a therapeutically effective amount of a modulator of the human enzyme TACE to a patient in need of such treatment.
• inhibitor refers to a compound or chemical substance that substantially eliminates or reduces the enzymatic activity of TACE.
• substantially means a reduction of at least 20%, preferably at least 30%, more preferably at least 50%, and more preferably at least 70% or 90%. More particularly, it may be a compound that interacts with, and blocks, the catalytic site of the enzyme.
• a preferred inhibitor interacts with the enzyme in solution at inhibitor concentrations of less than 1 ⁇ M, preferably less than 0.1 ⁇ M, more preferably less than 0.01 ⁇ M.
• the modulator compound may be an anti-TACE inhibitory antibody, preferably a monoclonal antibody.
• an inhibitory antibody is administered in an amount sufficient to obtain a plasma concentration of about 0.01 ⁇ g per ml to about 100 ⁇ g / ml, preferably from about 1 ⁇ g per ml to about 5 ⁇ g / ml.
• Preferred TACE inhibitors include W-3646, Ro-32-7315, GW-3333, apratastat or (3S) -N-hydroxy-4 - [[4 - [(4-hydroxybut-2-ynyl) oxy] phenyl] sulfonyl] -2,2-dimethylthiomorpholine-3-carboxamide, GW-4459, CGS-33090A, DPC-333, TNF-484, WTACE2, SP-057, SL-422, FYK-1388, and KB-R7785.
• TACE inhibitors 3- [3- [N-isopropyl-N- (4-methoxyphenylsulfonyl) amino] -phenyl] -3- (3-pyridyl) -2 (E) -propenohydroxamic acid, ( 2R, 3S) -3- (formylhydroxyamino) -4-methyl-2- (2-methylpropyl) -N - [(1S, 2S) -2-methyl-1 - [(2-pyridinylamino) carbonyl] butyl] pentanamide, (2R, 3S) -3- (formylhydroxyamino) -N- [(IS) -4-
• the inhibiting compounds are formulated within a pharmaceutical composition, in association with a pharmaceutically acceptable vehicle.
• These compositions may be administered, for example, orally, enterally, parenterally, or topically.
• the pharmaceutical composition is applied topically.
• the pharmaceutical composition may be in the form of tablets, capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres or lipid vesicles or polymers for controlled release.
• the pharmaceutical composition may be in the form of solutions or suspensions for infusion or for injection.
• the pharmaceutical composition is more particularly intended for the treatment of skin and mucous membranes and may be in the form of ointments, creams, milks, ointments, powders, soaked swabs, solutions, gels , sprays, lotions or suspensions, patches. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or polymeric patches or hydrogels allowing controlled release.
• This composition for topical application may be in anhydrous form, in aqueous form or in the form of an emulsion.
• the pharmaceutical composition is in the form of a gel, a cream or a lotion.
• the pharmaceutical composition may further contain inert additives or combinations of these additives, such as
• preserving agents such as esters of parahydroxybenzoic acid; stabilizing agents;
• osmotic pressure modifying agents emulsifying agents
• UV-A and UV-B filters are UV-A and UV-B filters
• antioxidants such as alpha-tocopherol, butylhydroxyanisole or butylhydroxytoluene, superoxide dismutase, ubiquinol or certain metal chelators.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Biotechnology (AREA)
• Biophysics (AREA)
• Analytical Chemistry (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Molecular Biology (AREA)
• Physics & Mathematics (AREA)
• Dermatology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Pyridine Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38961832

Family Applications (1)

Country Status (6)

Families Citing this family (2)

Family Cites Families (6)

• 2007
  • 2007-06-18 FR FR0755819A patent/FR2917427B1/fr not_active Expired - Fee Related
• 2008
  • 2008-06-18 JP JP2010512749A patent/JP2010532658A/ja active Pending
  • 2008-06-18 EP EP08806020A patent/EP2160606A2/de not_active Withdrawn
  • 2008-06-18 WO PCT/FR2008/051085 patent/WO2009004247A2/fr not_active Ceased
  • 2008-06-18 CA CA2690593A patent/CA2690593A1/en not_active Abandoned
• 2009
  • 2009-12-17 US US12/640,029 patent/US20100168089A1/en not_active Abandoned
• 2013
  • 2013-10-01 JP JP2013206168A patent/JP2014051500A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events